Contrast Induced Kidney Injury, Infamous Problem with No Magical Solutions

In patients at high risk of developing kidney complications undergoing angiography, we did not observe benefits when administering intravenous sodium bicarbonate vs. saline, or oral N-acetylcysteine vs. placebo, as to the prevention of death, dialysis or persistent deterioration of kidney function at 90 days, or the prevention of contrast induced kidney failure.

AngiographyMany small studies have looked into different strategies to prevent iodine contrast induced kidney injury with promising results, which have been recently unmasked by the NEJM publication of this large randomized controlled study testing two of the most popular strategies (sodium bicarbonate and N-acetylcysteine).

 

Intravenous sodium bicarbonate and acetylcysteine are widely used in the hope that they will prevent contrast induced kidney failure after angiography but there is no conclusive evidence as to its efficacy.

 

The present study used a 2×2 factorial design and randomized 5177 patients at high risk of kidney complications undergoing angiography to 1.26% sodium bicarbonate vs. 0.9% saline and 5 days of oral N-acetylcysteine vs placebo.


Read also: Peri-Procedural Infarction: More Frequent than and Not as Innocent as We Thought.


Primary end point was a composite of death, need of dialysis, persistent increase of at least 50% of baseline creatinine levels at 90 days. Contrast induced kidney failure was a secondary end point.

 

After interim analysis, the study was interrupted seeing that no interaction was found between interventions and primary end point (p=0.33), and therefore including more patients would not change outcomes.

 

Primary end point occurred in 4.4% of the sodium bicarbonate group vs 4.7% of patients receiving saline (OR 0.93, CI 0.72-1.22; p=0.62) and in 4.6% of patients receiving N-acetylcysteine vs 4.5% of patients receiving placebo (OR 1.02, IC 0.78 a 1.33; p=0.88).


Read also: TAVR in Patients with Classical Low Flow, Low Gradient.


There were no differences between the groups as regards contrast induced kidney injury.

 

Conclusion

Sodium bicarbonate and N-acetylcysteine do not reduce contrast induced kidney failure in patients at high risk of renal complications undergoing angiography.

Original title: Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. The PRESERVE Trial Group

Reference: S.D. Weisbord et al. N Engl J Med. 2018 Feb 15;378(7):603-614.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...